Ontology highlight
ABSTRACT: Background
The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anaemia.Methods
In this randomized, open-label and multi-centre trial conducted in the USA, patients were randomized 2:1 to a single dose of 1000?mg IIM or iron sucrose (IS) administered as 200?mg IV injections up to five times within a 2-week period. The co-primary endpoints were serious or severe hypersensitivity reactions and change in haemoglobin (Hb) from baseline to Week 8. Secondary endpoints included incidence of composite cardiovascular adverse events (AEs).Results
A total of 1538 patients were enrolled (mean estimated glomerular filtration rate 35.5?mL/min/1.73?m2). The co-primary safety objective was met based on no significant difference in the incidence of serious or severe hypersensitivity reactions in the IIM and IS groups [0.3% versus 0%; risk difference: 0.29% (95% confidence interval: -0.19; 0.77; P?>?0.05)]. Incidence of composite cardiovascular AEs was significantly lower in the IIM versus IS group (4.1% versus 6.9%; P?=?0.025). Compared with IS, IIM led to a more pronounced increase in Hb during the first 4?weeks (P???0.021), and change in Hb to Week 8 showed non-inferiority, confirming that the co-primary efficacy objective was met.Conclusions
Compared with multiple doses of IS, a single dose of IIM induced a non-inferior 8-week haematological response, comparably low rates of hypersensitivity reactions, and a significantly lower incidence of composite cardiovascular AEs.
SUBMITTER: Bhandari S
PROVIDER: S-EPMC7771981 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Bhandari Sunil S Kalra Philip A PA Berkowitz Mario M Belo Diogo D Thomsen Lars L LL Wolf Myles M
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20210101 1
<h4>Background</h4>The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anaemia.<h4>Methods</h4>In this randomized, open-label and multi-centre trial conducted in the USA, patients were randomized 2:1 to a single dose of 1000 mg IIM or ir ...[more]